Neoplasms

All Conditions

Rare Diseases

Hemangioendothelioma

Hemangioendothelioma, Epithelioid

Hemangiosarcoma

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasms, Vascular Tissue

Hemangioma

Soft Tissue Sarcoma

* Eribulin administered twice per cycle intravenously
* Each cycle contains 21 days
* Dosing is per the FDA label for other cancers

It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die

Eribulin

Gregory Cote, MD, PhD

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific disease but it has been approved for other uses.

In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.

Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Partial response rate plus complete response rate by RECIST 1.1

Objective Response plus Stable Disease Rate at 24 weeks

Summary of the treatment related adverse events experienced by study participants as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	NCT03331250	Angiosarcoma Epithelioid Hem...	Eribulin	18 Years -	Massachusetts General Hospital
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	NCT03331250	Angiosarcoma Epithelioid Hem...	Eribulin	18 Years -	Massachusetts General Hospital
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	NCT03331250	Angiosarcoma Epithelioid Hem...	Eribulin	18 Years -	Massachusetts General Hospital

Spots Global Cancer Trial Database for epithelioid hemangioendothelioma